| Medical and Health Sciences | Lifetime | 476 | NL 12 | 99.98 |
| Cardiology and Cardiovascular Medicine | Lifetime | 47 | NL 3 | 99.96 |
| Hematology | Lifetime | 393 | NL 13 | 97.62 |
| Complementary and Alternative Medicine | Lifetime | 516 | NL 6 | 96.57 |
| Nephrology | Lifetime | 392 | NL 10 | 96.49 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 234 | NL 11 | 98.17 |
| Heart Failure Treatment and Management | Lifetime | 15 | NL 1 | 99.93 |
| Cardiovascular Function and Risk Factors | Lifetime | 56 | NL 2 | 99.89 |
| Erythropoietin and Anemia Treatment | Lifetime | 7 | NL 1 | 99.69 |
| Cardiac pacing and defibrillation studies | Lifetime | 41 | NL 4 | 99.80 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 152 | NL 14 | 99.53 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 188 | NL 8 | 99.43 |
| Iron Metabolism and Disorders | Lifetime | 120 | NL 2 | 98.88 |
| Cardiac Arrhythmias and Treatments | Lifetime | 308 | NL 16 | 99.13 |
| Cardiac Health and Mental Health | Lifetime | 132 | NL 7 | 98.75 |
| Galectins and Cancer Biology | Lifetime | 126 | NL 6 | 98.32 |
| Cardiovascular Issues in Pregnancy | Lifetime | 124 | NL 7 | 98.67 |
| Potassium and Related Disorders | Lifetime | 46 | NL 3 | 98.87 |
| Peptidase Inhibition and Analysis | Lifetime | 431 | NL 10 | 98.40 |
| Medication Adherence and Compliance | Lifetime | 89 | NL 2 | 98.20 |
| Heart Rate Variability and Autonomic Control | Lifetime | 463 | NL 15 | 98.42 |
| Blood Pressure and Hypertension Studies | Lifetime | 416 | NL 14 | 98.75 |
| Acute Kidney Injury Research | Lifetime | 147 | NL 5 | 98.20 |
| Dialysis and Renal Disease Management | Lifetime | 305 | NL 19 | 98.47 |
| Cardiovascular and exercise physiology | Lifetime | 389 | NL 12 | 98.29 |
| Heart rate and cardiovascular health | Lifetime | 25 | NL 2 | 98.13 |
| Cardiac Structural Anomalies and Repair | Lifetime | 615 | NL 17 | 98.28 |
| Cardiovascular Disease and Adiposity | Lifetime | 538 | NL 17 | 97.37 |
| Chronic Kidney Disease and Diabetes | Lifetime | 603 | NL 16 | 96.83 |
| Signaling Pathways in Disease | Lifetime | 622 | NL 12 | 94.34 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 455 | NL 31 | 92.35 |
| Macrophage Migration Inhibitory Factor | Lifetime | 357 | NL 5 | 90.16 |
| Cardiac Fibrosis and Remodeling | Lifetime | 924 | NL 39 | 90.02 |
| Telomeres, Telomerase, and Senescence | Lifetime | 867 | NL 20 | 89.34 |
| GDF15 and Related Biomarkers | Lifetime | 377 | NL 9 | 85.10 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 592 | NL 18 | 80.95 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 61 | NL 2 | 96.72 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 257 | NL 11 | 98.04 |
| Heart Failure Treatment and Management | 2021-2025 | 148 | NL 8 | 98.21 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 558 | NL 25 | 94.04 |
| Electrolyte and hormonal disorders | 2021-2025 | 146 | NL 7 | 87.72 |
| Acute Kidney Injury Research | 2021-2025 | 580 | NL 9 | 82.32 |
| Potassium and Related Disorders | 2021-2025 | 232 | NL 11 | 80.65 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 247 | NL 8 | 79.21 |
| GDF15 and Related Biomarkers | 2021-2025 | 231 | NL 3 | 72.45 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 342 | NL 9 | 51.70 |
